Neurocrine Biosciences Presents Post Hoc Data Analysis in Congenital Adrenal Hyperplasia at ESPE 2023

Uncategorized
September 21, 2023
img: Featured

SAN DIEGO , Sept. 21, 2023 /PRNewswire/ — Neurocrine Biosciences, Inc.  (Nasdaq: NBIX), today announced that it will present a new post hoc analysis of Phase 2 data of the investigational drug crinecerfont in adolescent patients with classic congenital adrenal hyperplasia (CAH) due to

Uncategorized